Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance

Allen, Alex; Carville, Serena; McKenna, Frank

doi:10.1136/bmj.k3015

Cited by 51 publications

(54 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Literature search was performed under the following principles: (1) guidelines should be developed by the international network or the national association of rheumatology; (2) guidelines should be published after 2015; and (3) guidelines should be written in English or Korean. Following the review, six guidelines were selected for the management of RA and AS [9,10,12,17,18,25,26]. The Korean guidelines for tuberculosis (TB) and hepatitis B virus (HBV) infection, published by the Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) and the Korean Association for the Study of the Liver, respectively, were also included in the development of the clinical consensus statement [27,28].…”

Section: Literature Searchmentioning

confidence: 99%

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus

Park

Kim

Jung

et al. 2020

Korean J Intern Med

View full text Add to dashboard Cite

Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bD-MARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, "Expert consensus for the use of bDMARDs drugs for inflammatory arthritis in Korea," is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.

show abstract

Section: Literature Searchmentioning

confidence: 99%

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus

Park

Kim

Jung

et al. 2020

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by progressive joint destruction and pain and swelling of joints. RA affects 1% of the UK population [9].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

Autoimmunity and the Oral Cavity

Reilly

Johnston

Culshaw

2019

Curr Oral Health Rep

View full text Add to dashboard Cite

Purpose of Review This review aims to make the oral health practitioner and researcher aware of autoimmune diseases that present in the mouth and have implications for oral health. Specifically, the autoimmune pathophysiology, examples of treatments, sequelae, and impact on oral health will be discussed. The limitations of our current knowledge and understanding of these diseases will also be highlighted. Recent Findings Over the past decade, it has become clear that there is a bidirectional relationship between oral health and autoimmune disease at other body sites; including diabetes and rheumatoid arthritis. Improving the oral health of patients with autoimmune diseases may reduce morbidity associated with such diseases. Summary Autoimmune diseases impact the oral cavity both directly and indirectly and are increasing in prevalence. As such, there is a growing need for the oral health practitioners to be aware of how autoimmune disease impacts the oral cavity. Further research is necessary to improve our understanding of the bidirectional relationship between oral health and autoimmune disease.

show abstract

“…The basic pathological manifestations are synovitis, pannus formation, and articular cartilage and bone destruction gradually occur, which eventually leads to joint deformity and dysfunction [1]. RA main age of onset is 40-60 years old [2]. The application of anti-rheumatic drugs and biological agents has delayed the progress of RA bone destruction, a rate of RA patients receive total knee arthroplasty (TKA) has gradually decreased over the past decades.…”

Section: Introductionmentioning

confidence: 99%

Multiple-Dose Intravenous Tranexamic Acid in Total Knee Arthroplasty in Patients with Rheumatoid Arthritis: A Randomized Controlled Study

Kang

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To identify the efficacy and safety of multiple doses of intravenous tranexamic acid (IV-TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA) who underwent primary unilateral total knee arthroplasty (TKA).Methods: In this single-center, single-blind randomized controlled clinical trial, ten male and 87 female participants aged 50–75 years, with RA who underwent unilateral primary TKA were randomly assigned (1:1) to receive a single dose of IV-TXA (1 g) for 3 h (group A) or three doses of IV-TXA (1 g) for 3, 6, and 12 h (group B) postoperatively. Primary outcomes were total red blood cell loss (TBL), hidden red blood loss (HBL) and maximum hemoglobin (Hb) drop. Secondary outcomes were transfusion rate and levels of D-dimer. All parameters were measured post-operatively during inpatient hospital stay.Results: Between September 2019 and May 2020, 104 participants were randomized. 7 were lost follow-up. Mean TBL, HBL, and maximum Hb drop in group B (506.1 ± 227.0 mL, 471.6 ± 224.0 mL, and 17.5 ± 7.7 g/L, respectively) were significantly lower than those in groups A (608.8 ± 244.8 mL, P = 0.035; 574.0 ± 242.3 mL, P = 0.033; and 23.42 ± 9.2 g/L, P = 0.001, respectively). No episode of transfusion occurred. D-dimer level was lower in group B than in group A on post-operative day 1 (P < 0.001), and the incidence of thromboembolic events was similar between the two groups (P > 0.05). Conclusion: Three doses of post-operative IV-TXA could further reduced blood loss, maximum Hb drop, and diminished the postoperative fibrinolytic responses without increasing the risk of complications.Trial registration: The trial was registered in Chinese Clinical Trial Registry (ChiCTR1900025013).Name of the registry: Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis after total knee arthroplasty. Prospective registration, ChiCTR1900025013. Registered 7 August 2019, http://www.chictr.org.cn/showproj.aspx?proj=41375

show abstract

Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance

Cited by 51 publications

References 4 publications

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus

Autoimmunity and the Oral Cavity

Multiple-Dose Intravenous Tranexamic Acid in Total Knee Arthroplasty in Patients with Rheumatoid Arthritis: A Randomized Controlled Study

Contact Info

Product

Resources

About